Clinical risk stratification: Development and validation of the DAAE score, a tool for estimating patient risk of transition to secondary progressive multiple sclerosis
Tom Fuchs(Amsterdam Neuroscience), Menno M. Schoonheim(Amsterdam Neuroscience), Tomáš Uher(Charles University), Ralph H. B. Benedict(Jacobs Institute), Michael G. Dwyer(Buffalo Psychiatric Center), Niels Bergsland(Buffalo Psychiatric Center), Frederik Barkhof(Netherlands Institute for Neuroscience), Julia R. Jelgerhuis(Amsterdam Neuroscience), Bianca Weinstock‐Guttman(ECD for the Masses (United States)), Joep Killestein(Amsterdam UMC Location Vrije Universiteit Amsterdam), Robert Zivadinov(Yale University), Tetyana Pryshchepova(Amsterdam Neuroscience), Bernard M.J. Uitdehaag(Amsterdam UMC Location Vrije Universiteit Amsterdam), Dejan Jakimovski(University at Buffalo, State University of New York), Eva Strijbis(Amsterdam University Medical Centers)
Cited by 5
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
|Multiple Sclerosis Journal|2020|2.5k